• +1-646-491-9876
    • +91-20-67278686

    Search

    Bone Fracture-Pipeline Review H2 2017

    Bone Fracture-Pipeline Review H2 2017

    • Report Code ID: RW00011060440
    • Category Life Sciences
    • No. of Pages 110
    • Publication Month Sep-17
    • Publisher Name Global Markets Direct
    Bone Fracture-Pipeline Review, H2 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Bone Fracture-Pipeline Review, H2 2017, provides an overview of the Bone Fracture (Musculoskeletal Disorders) pipeline landscape.

    Fractures are simply a break in a bone caused by forces that exceed the strength of the osseous tissue in the bone. Signs and symptoms of a fracture include swelling or bruising over a bone, deformity of an arm or leg, loss of function in the injured area and in compound fractures, bone protruding from the skin.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Bone Fracture-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Bone Fracture (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Bone Fracture (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Bone Fracture and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 7, 1, 16 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 3 molecules, respectively.

    Bone Fracture (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    -The pipeline guide provides a snapshot of the global therapeutic landscape of Bone Fracture (Musculoskeletal Disorders).
    -The pipeline guide reviews pipeline therapeutics for Bone Fracture (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    -The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    -The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    -The pipeline guide reviews key companies involved in Bone Fracture (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
    -The pipeline guide evaluates Bone Fracture (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    -The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    -The pipeline guide reviews latest news related to pipeline therapeutics for Bone Fracture (Musculoskeletal Disorders)

    Reasons to buy

    -Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    -Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    -Find and recognize significant and varied types of therapeutics under development for Bone Fracture (Musculoskeletal Disorders).
    -Classify potential new clients or partners in the target demographic.
    -Develop tactical initiatives by understanding the focus areas of leading companies.
    -Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    -Formulate corrective measures for pipeline projects by understanding Bone Fracture (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    -Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    Table of Contents 2
    List of Tables 3
    List of Figures 4
    Introduction 5
    Global Markets Direct Report Coverage 5
    Bone Fracture-Overview 6
    Bone Fracture-Therapeutics Development 7
    Pipeline Overview 7
    Pipeline by Companies 8
    Pipeline by Universities/Institutes 11
    Products under Development by Companies 12
    Products under Development by Universities/Institutes 14
    Bone Fracture-Therapeutics Assessment 15
    Assessment by Target 15
    Assessment by Mechanism of Action 17
    Assessment by Route of Administration 19
    Assessment by Molecule Type 21
    Bone Fracture-Companies Involved in Therapeutics Development 23
    American Gene Technologies International Inc 23
    BiologicsMD Inc 23
    Biopharm GmbH 23
    Bone Therapeutics SA 24
    Cellmid Ltd 24
    Chrysalis BioTherapeutics Inc 25
    Entera Bio Ltd 25
    Escape Therapeutics Inc 25
    ethris GmbH 26
    Kuros Biosciences AG 26
    Laboratorios SALVAT SA 27
    Novartis AG 27
    Pluristem Therapeutics Inc 28
    TissueGene Inc 28
    Viking Therapeutics Inc 29
    Bone Fracture-Drug Profiles 30
    ALLOB-Drug Profile 30
    bimagrumab-Drug Profile 34
    BMD-1221-Drug Profile 37
    cannabidiol-Drug Profile 38
    Cell Therapy for Non-Union Fractures-Drug Profile 41
    Cyndacel-M-Drug Profile 42
    denosumab biosimilar-Drug Profile 44
    dibotermin alfa biosimilar-Drug Profile 45
    Drugs to Modulate Bone Morphogenetic Protein for Osteoarthritis and Fracture-Drug Profile 46
    Drugs to Modulate PPAR-Delta for Metabolic and Musculoskeletal Disorders-Drug Profile 47
    Gene Therapy for Bone Fracture-Drug Profile 48
    Gene Therapy for Bone Fracture-Drug Profile 49
    Gene Therapy to Activate BMP2 and VEGF for Bone Fracture-Drug Profile 50
    HCSVT-1001-Drug Profile 51
    KAL-436-Drug Profile 52
    KAL-439-Drug Profile 54
    KUR-111-Drug Profile 55
    KUR-113-Drug Profile 57
    LWnt-3a-Drug Profile 59
    Monoclonal Antibody to Inhibit Midkine for Bone Fractures-Drug Profile 60
    Oligonucleotide to Activate BMP-2 for Bone Fracture-Drug Profile 61
    OsteoStem-Drug Profile 62
    PLX-PAD-Drug Profile 63
    PREOB-Drug Profile 74
    Recombinant Peptide to Agonize PTH1R for Bone Fracture-Drug Profile 77
    Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease-Drug Profile 78
    rusalatide acetate-Drug Profile 80
    S-008399-Drug Profile 84
    Small Molecules for Metabolic and Musculoskeletal Disorders-Drug Profile 85
    Small Molecules for Musculoskeletal and Metabolic Disorders-Drug Profile 86
    SPI-86-Drug Profile 87
    Synthetic Peptide for Osteoporosis and Bone Fracture-Drug Profile 88
    TG-B-Drug Profile 89
    VK-5211-Drug Profile 90
    Bone Fracture-Dormant Projects 93
    Bone Fracture-Discontinued Products 94
    Bone Fracture-Product Development Milestones 95
    Featured News & Press Releases 95
    Appendix 106
    Methodology 106
    Coverage 106
    Secondary Research 106
    Primary Research 106
    Expert Panel Validation 106
    Contact Us 106
    Disclaimer 107

    List of Tables
    Number of Products under Development for Bone Fracture, H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
    Number of Products under Development by Universities/Institutes, H2 2017
    Products under Development by Companies, H2 2017
    Products under Development by Companies, H2 2017 (Contd..1), H2 2017
    Products under Development by Universities/Institutes, H2 2017
    Number of Products by Stage and Target, H2 2017
    Number of Products by Stage and Mechanism of Action, H2 2017
    Number of Products by Stage and Route of Administration, H2 2017
    Number of Products by Stage and Molecule Type, H2 2017
    Bone Fracture-Pipeline by American Gene Technologies International Inc, H2 2017
    Bone Fracture-Pipeline by BiologicsMD Inc, H2 2017
    Bone Fracture-Pipeline by Biopharm GmbH, H2 2017
    Bone Fracture-Pipeline by Bone Therapeutics SA, H2 2017
    Bone Fracture-Pipeline by Cellmid Ltd, H2 2017
    Bone Fracture-Pipeline by Chrysalis BioTherapeutics Inc, H2 2017
    Bone Fracture-Pipeline by Entera Bio Ltd, H2 2017
    Bone Fracture-Pipeline by Escape Therapeutics Inc, H2 2017
    Bone Fracture-Pipeline by ethris GmbH, H2 2017
    Bone Fracture-Pipeline by Kuros Biosciences AG, H2 2017
    Bone Fracture-Pipeline by Laboratorios SALVAT SA, H2 2017
    Bone Fracture-Pipeline by Novartis AG, H2 2017
    Bone Fracture-Pipeline by Pluristem Therapeutics Inc, H2 2017
    Bone Fracture-Pipeline by TissueGene Inc, H2 2017
    Bone Fracture-Pipeline by Viking Therapeutics Inc, H2 2017
    Bone Fracture-Dormant Projects, H2 2017
    Bone Fracture-Discontinued Products, H2 2017

    List of Figures
    Number of Products under Development for Bone Fracture, H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products under Development by Universities/Institutes, H2 2017
    Number of Products by Top 10 Targets, H2 2017
    Number of Products by Stage and Top 10 Targets, H2 2017
    Number of Products by Top 10 Mechanism of Actions, H2 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
    Number of Products by Routes of Administration, H2 2017
    Number of Products by Stage and Routes of Administration, H2 2017
    Number of Products by Top 10 Molecule Types, H2 2017
    Number of Products by Stage and Top 10 Molecule Types, H2 2017
    American Gene Technologies International Inc
    BiologicsMD Inc
    Biopharm GmbH
    Bone Therapeutics SA
    Cellmid Ltd
    Chrysalis BioTherapeutics Inc
    Entera Bio Ltd
    Escape Therapeutics Inc
    ethris GmbH
    Kuros Biosciences AG
    Laboratorios SALVAT SA
    Novartis AG
    Pluristem Therapeutics Inc
    TissueGene Inc
    Viking Therapeutics Inc

    Request for Sample

    Report Url https://www.reportsweb.com//bone-fracture-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//bone-fracture-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//bone-fracture-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments